Homology Medicines, Inc. (FIXX) financial statements (2020 and earlier)

Company profile

Business Address ONE PATRIOTS PARK
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments262215
Cash and cash equivalents5438
Short-term investments209177
Other undisclosed current assets47
Total current assets:267222
Noncurrent Assets
Property, plant and equipment4336
Other undisclosed noncurrent assets12
Total noncurrent assets:4437
TOTAL ASSETS:311259
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities820
Accounts payable316
Accrued liabilities10
Employee-related liabilities53
Deferred revenue1
Deferred rent credit11
Other undisclosed current liabilities25
Total current liabilities:1225
Noncurrent Liabilities
Liabilities, other than long-term debt409
Deferred revenue30
Deferred rent credit109
Other undisclosed noncurrent liabilities 29
Total noncurrent liabilities:4039
Total liabilities:5264
Stockholders' equity
Stockholders' equity attributable to parent259195
Common stock00
Additional paid in capital458292
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(200)(97)
Total stockholders' equity:259195
TOTAL LIABILITIES AND EQUITY:311259

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:24
Operating expenses(112)(65)
Operating loss:(110)(62)
Nonoperating income
(Other Nonoperating income)
64
Net loss available to common stockholders, diluted:(104)(57)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(104)(57)
Comprehensive loss:(104)(57)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive loss, net of tax, attributable to parent:(104)(57)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: